24,473 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by GW Henssler & Associates Ltd.

GW Henssler & Associates Ltd. purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 24,473 shares of the pharmaceutical company's stock, valued at approximately $11,382,000.

Several other institutional investors also recently bought and sold shares of VRTX. Capital World Investors raised its holdings in shares of Vertex Pharmaceuticals by 17.2% during the first quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company's stock valued at $10,687,339,000 after acquiring an additional 3,761,414 shares during the last quarter. Vanguard Group Inc. boosted its stake in Vertex Pharmaceuticals by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company's stock worth $9,479,011,000 after purchasing an additional 394,338 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Vertex Pharmaceuticals by 61.0% during the first quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company's stock worth $2,401,000,000 after buying an additional 2,176,218 shares in the last quarter. Jennison Associates LLC raised its position in shares of Vertex Pharmaceuticals by 21.2% in the first quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company's stock valued at $1,999,080,000 after buying an additional 837,461 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Vertex Pharmaceuticals by 10.4% in the first quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company's stock worth $1,080,296,000 after buying an additional 244,336 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 1.3 %

Shares of VRTX stock traded down $6.01 during trading on Tuesday, hitting $470.36. 999,418 shares of the company were exchanged, compared to its average volume of 1,167,135. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.90 and a twelve month high of $510.64. The business's 50-day simple moving average is $475.37 and its 200 day simple moving average is $463.27. The firm has a market capitalization of $121.40 billion, a price-to-earnings ratio of -234.67 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($12.54) by ($0.29). The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company's revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.53 earnings per share. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Truist Financial restated a "buy" rating and set a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Scotiabank initiated coverage on Vertex Pharmaceuticals in a research note on Wednesday, October 16th. They issued a "sector perform" rating and a $480.00 target price for the company. Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the company an "equal weight" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an "overweight" rating in a report on Monday, August 5th. Finally, UBS Group upped their price objective on Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $492.92.

Insider Activity

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares of the company's stock, valued at approximately $4,987,006. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares in the company, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,005 shares of company stock valued at $5,988,066 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.